This HTML5 document contains 92 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/wikipedia/
n20http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/bindingdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/kegg-drug/
n19http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n29http://www.rxlist.com/cgi/generic/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n24http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB01166/identifier/chebi/
n22http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01166
rdf:type
n3:Drug
n3:description
Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease. [Wikipedia]
n3:dosage
n25:271B4D35-363D-11E5-9242-09173F13E4C5 n25:271B4D36-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
11-13 hours.
n3:indication
For the reduction of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
owl:sameAs
n16:DB01166 n19:DB01166
dcterms:title
Cilostazol
adms:identifier
n6:50070490 n7:31401 n8:46506317 n11:2754 n12:D01896 n13:0378-2979-91 n14:2652 n17:DB01166 n26:Cilostazol n28:PA164746334
n3:mechanismOfAction
Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.
n3:packager
n20:271B4D2F-363D-11E5-9242-09173F13E4C5 n20:271B4D30-363D-11E5-9242-09173F13E4C5 n20:271B4D29-363D-11E5-9242-09173F13E4C5 n20:271B4D2A-363D-11E5-9242-09173F13E4C5 n20:271B4D27-363D-11E5-9242-09173F13E4C5 n20:271B4D28-363D-11E5-9242-09173F13E4C5 n20:271B4D2D-363D-11E5-9242-09173F13E4C5 n20:271B4D2E-363D-11E5-9242-09173F13E4C5 n20:271B4D2B-363D-11E5-9242-09173F13E4C5 n20:271B4D2C-363D-11E5-9242-09173F13E4C5 n20:271B4D22-363D-11E5-9242-09173F13E4C5 n20:271B4D25-363D-11E5-9242-09173F13E4C5 n20:271B4D26-363D-11E5-9242-09173F13E4C5 n20:271B4D23-363D-11E5-9242-09173F13E4C5 n20:271B4D24-363D-11E5-9242-09173F13E4C5 n20:271B4D21-363D-11E5-9242-09173F13E4C5 n20:271B4D1F-363D-11E5-9242-09173F13E4C5 n20:271B4D20-363D-11E5-9242-09173F13E4C5 n20:271B4D1E-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine. Cilostazol is eliminated predominately by metabolism and subsequent urinary excretion of metabolites. The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%). No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydro-cilostazol. About 30% of the dose was excreted in urine as 4'-trans-hydroxy-cilostazol.
n3:synonym
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril 3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one Cilostazole Cilostazolum 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
n3:toxicity
Information on acute overdosage with cilostazol in humans is limited. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmias. The oral LD<sub>50</sub> of cilostazol is >5.0 g/kg in mice and rats and >2.0 g/kg in dogs.
n3:foodInteraction
Take on an empty stomach, a lipid rich meal will increase absorption. Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can significantly increase serum levels of this product.
n3:proteinBinding
95-98%
n3:synthesisReference
Marioara Mendelovici, "Processes for preparing cilostazol." U.S. Patent US20020099213, issued July 25, 2002.
n9:hasConcept
n10:M0132637
foaf:page
n24:cilostazol.html n29:cilostaz.htm
n3:IUPAC-Name
n4:271B4D3B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4D41-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4D40-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4D3D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4D3E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4D3F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4D39-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4D52-363D-11E5-9242-09173F13E4C5 n4:271B4D37-363D-11E5-9242-09173F13E4C5 n4:271B4D3A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4D38-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:B01AC23
n3:H-Bond-Acceptor-Count
n4:271B4D47-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4D48-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4D42-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4D43-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4D45-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4D44-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4D46-363D-11E5-9242-09173F13E4C5
n3:absorption
Cilostazol is absorbed after oral administration. A high fat meal increases absorption, with an approximately 90% increase in C<sub>max</sub> and a 25% increase in AUC. Absolute bioavailability is not known.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
73963-72-1
n3:category
n3:containedIn
n18:271B4D34-363D-11E5-9242-09173F13E4C5 n18:271B4D32-363D-11E5-9242-09173F13E4C5 n18:271B4D33-363D-11E5-9242-09173F13E4C5 n18:271B4D31-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4D4D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4D4F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4D50-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4D51-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4D4C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4D4B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4D4E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4D3C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4D49-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4D4A-363D-11E5-9242-09173F13E4C5